# A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Source: https://onco.cc/trials/nct04974398/  
OnCo record `nct04974398` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Penpulimab, Cisplatin, Carboplatin in nasopharyngeal carcinoma, run by Akeso, active and no longer recruiting.

## Summary

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT04974398 by Akeso, with 296 participants enrolled, started 2021-08-16 and due to reach its primary completion in 2026-02-23. Interventions recorded: Penpulimab, placebo. Conditions listed: Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04974398
- Phase: 3
- Setting: A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Sponsor: Akeso
- Enrolled: 296

## Sources

- ClinicalTrials.gov NCT04974398: https://clinicaltrials.gov/study/NCT04974398

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct04974398.json